Biopharmaceuticals

Biopharmaceuticals Contract Manufacturing Market Report 2023-2033

Fri, 19 May 2023 11:50:09 +0000

The Biopharmaceuticals Contract Manufacturing Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Every year, new and unique drug products and technologies come out. This changes the way biopharma works and what kinds of treatments are possible. This is partly because outsourcing gives them the ability and freedom to do so. Emerging and virtual companies that are driving the future pipeline depend heavily on external development partners, and not just for hard-to-make products. Even more well-known companies are signing contracts with CDMOs to get access to their resources and certain skills. In cell and gene therapy (CGT), many of the chemistry, manufacturing, and control (CMC) jobs, such as process development, analytical development, testing, manufacturing, and filling and finishing, ar...

$4,938.00

Automation in Biopharma Industry Market Report 2023-2033

Fri, 19 May 2023 11:50:09 +0000

The Automation in Biopharma Industry Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Automation in biopharma industry is a term used to describe the use of advanced technologies and automated systems in the biopharmaceutical industry to enhance the manufacturing process's efficiency, accuracy, and reliability. It can improve drug production's consistency and quality through various means.

The primary advantage of biopharma automation is that it enhances accuracy and precision. Automated systems can be programmed to perform tasks with increased accuracy and precision, reducing the likelihood of errors and inconsistencies that may affect drug quality. Biopharma automation can also reduce the risk of contamination by reducing the need for human intervention, thereby impro...

$4,938.00

Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Fri, 21 Oct 2022 15:17:16 +0000

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population. ...

$5,119.00

Leading BioPharma Companies: Capabilities, Goals and Strategies

Tue, 10 May 2022 11:27:19 +0000

In the dynamic and fragmented BioPharma industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.

Our collection of strategic assessments of leading BioPharma companies provides significant competitor information, analysis and insight critical to the development and implementation of effective business, marketing and R&D programs. The assessments include latest organizational and management developments, acquisitions and divestitures, marketing tactics, financial results, strengths and weaknesses, and strategic directions. ...

$0.00

Biopharmaceuticals Contract Manufacturing - Market Insights, Competitive Landscape and Market Forecast–2027

Wed, 27 Apr 2022 14:02:44 +0000

Biopharmaceuticals Contract Manufacturing Market By Product (Biologics [Monoclonal Antibodies (MABS), Proteins/Peptides, Vaccines, And Others], Biosimilars), By Source (Mammalian And Non-Mammalian), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to the increase in the outsourcing volume by key manufacturers and expansion in the services offered by CMOs The global biopharmaceuticals contract manufacturing market estimated to advance at a 7.38% CAGR during the forecast period from 2022 to 2027. The rise in the biopharmaceuticals contract manufacturing market is primarily owing to the growing R&D investments for the development of various biologics and biosimilars, the rise in the volume of outsourcing by the key biopharma giants, various advantages associated with contract manufacturing such as reductions in the overall investment for introducing a new drug in the market, and others. Also, the robust pipeline of biologics is likely to be responsible for driving the global biopharmaceuticals contract manufacturing market during the forecasted period f...

$4,750.00

Leading BioPharma Companies: Capabilities, Goals and Strategies

Thu, 02 Jan 2020 15:51:18 +0000

$0.00

Biopharmaceuticals Markets in China

Wed, 12 May 2021 15:00:05 +0000

China's demand for Biopharmaceuticals has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2010, 2015 and 2020) and long-term forecasts through 2025 and 2030 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews are cond...

$4,000.00

Biopharmaceuticals Industry Forecasts - China Focus

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Biopharmaceuticals industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovat...

$1,800.00

Biopharmaceuticals Companies in China

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Biopharmaceuticals industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is sufferi...

$1,800.00

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area

Mon, 09 Apr 2018 12:55:32 +0000

Summary

GlobalData’s "The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area", provides an insight-rich overview of the key events and trends that our analysts expect to occur during 2018. This forward-looking view of the industry identifies key events that will occur across the major therapeutic areas - oncology, immunology, neurology, cardiovascular diseases, metabolic disorders, infectious diseases, and ophthalmology - and provides analyst insight on the potential ramifications of each event.

2018 promises to be a year of continued innovation in the biopharmaceutical industry across therapy areas. In this report, GlobalData’s analysts highlight a selection of highly anticipated events, including regulatory approvals, product launches, and clinical trial milestones throughout the year.

Scope

For each therapeutic area, the report includes a timeline of events by quarter and analysis of each event. Selected events and insights include -
- Within the oncology space, GlobalData anticipate...

$500.00

Hemispherx Biopharma, Inc. (HEB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sun, 19 Jun 2016 18:07:50 +0000

Summary

Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company, which develops, manufactures and commercializes drug therapies for the treatments of viral and immune based chronic disorders. Its lead product candidates include Ampligen, a new class of specifically-configured ribonucleic acid compounds for the treatment of various diseases such as hepatitis B, hepatitis C, chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), HIV and cancers including kidney cancer and metastatic malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon For the multiple sclerosis, hepatitis C, HIV, west Nile virus, and SARS; and Alferon LDO (Low Dose Oral), an oral form of Alferon N Injection for influenza viruses. The company operates production facility in New Brunswick, New Jersey, which is designed to produce Alferon and Ampligen. Hemispherx is headquartered in Pennsylvania, the US.

Hemispherx Biopharma, Inc. (HEB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and tre...

$250.00

SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2016

Sat, 28 May 2016 18:39:51 +0000

Summary

Global Markets Direct’s, ‘SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the SK Biopharmaceuticals Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by SK Biopharmaceuticals Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and in...

$1,500.00